Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656650 | 1.00 | KDM4E (0.32) | KDM4ENPC1ALDH1A1HSP90AA1HPGD | |
| SCHEMBL5658394 | 0.87 | MEN1 (0.33) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL5658396 | 0.87 | MEN1 (0.33) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL5659091 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL5659089 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL5657612 | 0.85 | ALOX5 (0.31) | SMN1; SMN2 | |
| SCHEMBL5657615 | 0.85 | ALOX5 (0.31) | SMN1; SMN2 | |
| SCHEMBL5657381 | 0.83 | MEN1 (0.32) | KDM4EALDH1A1HTT | |
| SCHEMBL5657384 | 0.83 | MEN1 (0.32) | KDM4EALDH1A1HTT | |
| SCHEMBL5658290 | 0.82 | SMN1; SMN2 (0.36) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030130-B2 | Benzofuran derivatives and their use as antibacterial agents | ARPIDA AG (CH) | 2006-04-18 | — | — | US | disclosed |
| EP-1307445-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | EVOLVA SA (CH) | 2004-02-19 | — | — | US | disclosed |
| EP-1307445-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Arpida AG, (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010157-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | SBDS, BPTF, DCXR | KDM4E 1540/4885NPC1 2360/4885ALDH1A1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.